TickerFacts.

Compare

Vericel Corp vs Adaptive Biotechnologies Corp vs Iovance Biotherapeutics, Inc. vs Twist Bioscience Corp

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearVericel Corp
VCEL		Adaptive Biotechnologies Corp
ADPT		Iovance Biotherapeutics, Inc.
IOVA		Twist Bioscience Corp
TWST
Year ended2025-12-312025-12-312025-12-312025-09-30
Revenue$276.26M$276.98M$263.50M$376.57M
Revenue growth (YoY)+16.5%+54.8%+60.6%+20.3%
Gross margin74.4% (computed)74.2% (computed)34.3% (computed)50.7% (computed)
Operating margin4.0%-20.6%-153.1%-36.2%
Net margin6.0%-21.5%-148.4%-20.6%
Net income$16.52M-$59.50M-$390.98M-$77.67M
EPS (Diluted)$0.32-$0.39-$1.09-$1.30
Operating cash flow$51.91M-$45.99M-$302.41M-$47.63M
Free cash flow$24.75M-$48.95M-$336.24M-$75.63M
Cash & equivalents$100.09M$70.50M$163.08M$183.05M
Total assets$487.97M$512.74M$913.17M$641.86M
Total liabilities$133.33M$287.74M$214.59M$168.90M
Shareholders' equity$354.64M$218.79M$698.58M$472.96M
Return on year-end equity4.7%-27.2%-56.0%-16.4%
Shares outstanding50.62M153.78M411.94M60.63M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearVericel CorpAdaptive Biotechnologies CorpIovance Biotherapeutics, Inc.Twist Bioscience Corp
Latest$276.26M
Ended 2025-12-31		$276.98M
Ended 2025-12-31		$263.50M
Ended 2025-12-31		$376.57M
Ended 2025-09-30
1 year earlier$237.22M
Ended 2024-12-31		$178.96M
Ended 2024-12-31		$164.07M
Ended 2024-12-31		$312.97M
Ended 2024-09-30
2 years earlier$197.52M
Ended 2023-12-31		$170.28M
Ended 2023-12-31		$1.19M
Ended 2023-12-31		$245.11M
Ended 2023-09-30
3 years earlier$163.70M
Ended 2022-12-31		$185.31M
Ended 2022-12-31		n/a$203.56M
Ended 2022-09-30
4 years earlier$153.07M
Ended 2021-12-31		$154.34M
Ended 2021-12-31		n/a$132.33M
Ended 2021-09-30